Two recent clinical trials found that adding immunotherapy to standard chemoradiation did not improve survival for patients with limited-stage small-cell lung cancer or high-risk HPV-positive oropharyngeal cancer, though both studies revealed important insights about treatment delivery and radiation scheduling.
Recent studies reveal immunotherapy failed to improve survival in small-cell lung cancer when combined with chemoradiation, while timing of immunotherapy after radiation therapy affects outcomes in non-small cell lung cancer patients.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07554573 |
Assessment of Biosignature Classification of DCIS for RadioTherapy Benefit Post Lumpectomy (ABCD RT) |
NOT_YET_RECRUITING | PHASE3 |
| NCT07452458 |
Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma |
NOT_YET_RECRUITING | PHASE3 |
| NCT07441681 |
Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin |
NOT_YET_RECRUITING | PHASE3 |
| NCT07166406 |
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial |
RECRUITING | PHASE3 |
| NCT07097142 |
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study |
RECRUITING | PHASE3 |
| NCT06958328 |
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer |
RECRUITING | PHASE3 |
| NCT06748222 |
E-Mindfulness Approaches for Living After Breast Cancer |
RECRUITING | PHASE3 |
| NCT06745024 |
Comparing Radiation Therapy to Usual Treatment for Patients With High-Risk Bone Metastases That Are Not Causing Pain, PREEMPT Trial |
ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT06686771 |
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer |
RECRUITING | PHASE3 |
| NCT06592924 |
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response |
RECRUITING | PHASE3 |
